CD44 and cancer: Accordingly, the percentage of rare cell abnormality by quantity measured 80% and the frequency of CD44i35 fraction within CD44+ CRC (true-positive fraction) in each cancer cohort was significantly increased measuring on average 41.7% (Table 2).